US regulators should require NAION warnings on GLP-1 drug labels

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

CDC and HHS leadership, research integrity, bioethics, regulatory appointments, e-cigarette regulation, and global health funding.

Adherence to laws and safety standards.

Monitoring and prevention of adverse effects from medications.

FDA oversight of drug approvals, drug scheduling, pharmaceutical tariffs, medical device regulation, and drug safety enforcement.

Common and serious adverse reactions linked to GLP-1 drugs, including gastrointestinal symptoms, gallbladder issues, pancreatitis concerns, muscle loss, and long-term safety questions.

Federal food safety regulation, dietary guidelines, nutrition labeling, food additive oversight, and school nutrition programs.

FDA food additive oversight, GRAS loophole reform, food warning labels, artificial sweetener review, and school nutrition standards.